September 1st is World Chronic Lymphocytic Leukaemia (CLL) Day, the most common leukaemia in adults. Most patients with CLL respond well to treatment1
This discovery changes the view of the progression of leukaemia, opens the door to early diagnosis, and offers new treatment strategies.
The call for the presentation of applications for the I Estella Matutes Extraordinary Scholarship is open from September 19th to November 30th.
The grants from the European Haematology Association (EHA) are aimed at promoting the early careers of researchers and encouraging their involvement1
Researchers from IDIBAPS-Hospital Clínic and CNAG-CRG in Barcelona have led a study to draw the first 3D maps of the genome of healthy and cancerous1
The Spanish Agency of Medicines and Medical Devices (AEMPS) has approved CAR-T ARI-0001, developed by Hospital Clínic, as and advanced therapy drug o1
Immuneel Therapeutics Private Limited (Immuneel) today announced that it has entered into a multi-asset collaboration and licensing agreement with Ho1
A consortium of researchers from the Cancer Research Center of Ontario and the Hospital for Sick Children of Toronto, the Hospital Clínic-IDIBAPS of1
Researchers at IDIBAPS have published a study in Nature Communications in which they have deciphered the molecular basis of the genetic predispositio1
The latest advance in the field of immune therapies against cancer are the active and targeted CAR therapies. This treatment consists of obtaining th1
